Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

176
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
176

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The reliability of the modified lower extremity functional scale among adults living with HIV on antiretroviral therapy, in Rwanda, Africa.

SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance·2014
Same author

Endoscopy supply water and final rinse testing: five years of experience.

The Journal of hospital infection·2014
Same author

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.

Lung cancer (Amsterdam, Netherlands)·2014
Same author

Health risk estimates for groundwater and soil contamination in the Slovak Republic: a convenient tool for identification and mapping of risk areas.

Environmental geochemistry and health·2014
Same author

HOW TO…: Use Videodiscs in Medical Education, Part 1.

Medical teacher·2014
Same author

Videodiscs in Medical Education, part 2.

Medical teacher·2014
Same journal

Broad-Spectrum Antibiotics are Associated with worse Survival After Radical Treatment for Glioblastoma Multiforme: A Multicentre Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Exploring the Need for Plan Adaptation in Robustly Optimised Head and Neck Intensity Modulated Proton Therapy: A Dosimetric Perspective From Initial Institutional Experience.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Lifting the Lid on Best Practice in a Case of Oligometastatic Breast Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Standardisation of Imaging Surveillance for Patients With Metastatic Melanoma Stopping Immune Checkpoint Inhibitors.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Valuing Public Sector Data Assets: Methodological Perspectives From the Add-Aspirin Trial's Use of Healthcare Systems Data for Clinical Follow-Up.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Autologous Cell Therapy in Oncology: Current Landscape and Future Directions.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.1K

Endometrial Cancer: Analysing Patterns of Recurrence and Real-Life Outcome Data Using the 2020 ESGO-ESTRO-ESP Risk

R Karkia1, T R Nyakunengwa2, C Uwins1

  • 1Academic Department of Gynaecological Oncology, Royal Surrey NHS Foundation Trust, Surrey, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|June 28, 2024
PubMed
Summary
This summary is machine-generated.

The 2020 ESGO-ESTRO-ESP risk stratification system accurately predicts endometrial cancer recurrence and survival. Following current guidelines improves patient outcomes, especially in early-stage disease.

Keywords:
Endometrial cancerRisk stratificationRobotic surgery

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

248
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

Related Experiment Videos

Last Updated: Jun 22, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.1K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

248
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

Area of Science:

  • Gynecologic Oncology
  • Cancer Staging and Risk Stratification
  • Endometrial Cancer Research

Background:

  • Endometrial cancer incidence has increased significantly since the 1990s.
  • Projected to be the sixth leading cause of cancer death in women by 2035.
  • Need for accurate prognostic tools in early-stage disease.

Purpose of the Study:

  • Compare the 2018 FIGO staging system with the 2020 ESGO-ESTRO-ESP risk stratification.
  • Evaluate recurrence patterns in endometrial cancer.
  • Assess prognostic differences between staging systems for early-stage disease.

Main Methods:

  • Retrospective cohort study of 692 patients (2010-2017).
  • Kaplan-Meier survival analysis for overall survival (OS) and recurrence-free survival (RFS).
  • Cox regression and chi-square tests for prognostic factors and recurrence patterns.

Main Results:

  • Recurrence rate of 14.9% with a median time to recurrence of 17.1 months.
  • Significant differences in OS and RFS between low-risk and high-risk groups (p < 0.001).
  • Recurrence predicted by high-risk group, lymphovascular space invasion (LVSI), carcinosarcoma, and serous subtype.

Conclusions:

  • The 2020 ESGO-ESTRO-ESP system accurately stratifies endometrial cancer recurrence risk.
  • Patients treated according to current guidelines demonstrate significantly improved outcomes.
  • The system aids in predicting distant recurrence, with negative LVSI and Grade 1 cancers associated with decreased risk.